8-K filed November 28, 2023, 6:59 PM ET ticker SYRE CIK 0001636282

leadership confidence high sentiment positive materiality 0.75

Spyre Therapeutics appoints Cameron Turtle CEO; name change to Spyre, ticker SYRE effective Nov 28

Spyre Therapeutics, Inc.

Cameron Turtle, previously COO, appointed CEO and director; $625K base, 55% target bonus, option for 374K shares at $10.39.
Name change from Aeglea BioTherapeutics to Spyre Therapeutics; ticker changes from AGLE to SYRE effective Nov 28, 2023.
Directors Ivana Magovčević-Liebisch and Hunter Smith resign; Laurie Stelzer (chair audit) and Jeffrey Albers appointed to board.
Pipeline on track: SPY001 (anti-α4β7) FIH H1 2024; SPY002 (anti-TL1A) FIH H2 2024; SPY003 (anti-IL-23) IND 2025; cash $205M into 2026.

item 5.02 item 5.03 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Cameron Turtle

Chief Executive Officer

SYRE · Spyre Therapeutics, Inc.

Effective: 2023-11-22
Filed: November 28, 2023, 6:59 PM ET

appointed Cameron Turtle, DPhil, as Chief Executive Officer of the Company, effective as of November 22, 2023.

Departed

Hunter C. Smith

Director

SYRE · Spyre Therapeutics, Inc.

Effective: 2023-11-22
Filed: November 28, 2023, 6:59 PM ET

Ivana Magovčević-Liebisch, Ph.D., J.D. and Hunter C. Smith, M.B.A. resigned from the Board.

Departed

Ivana Magovčević-Liebisch

Director

SYRE · Spyre Therapeutics, Inc.

Effective: 2023-11-22
Filed: November 28, 2023, 6:59 PM ET

Ivana Magovčević-Liebisch, Ph.D., J.D. and Hunter C. Smith, M.B.A. resigned from the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Cameron Turtle was appointed as Chief Executive Officer at Spyre Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

appointed Cameron Turtle, DPhil, as Chief Executive Officer of the Company, effective as of November 22, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Hunter C. Smith resigned as Director at Spyre Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

Ivana Magovčević-Liebisch, Ph.D., J.D. and Hunter C. Smith, M.B.A. resigned from the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ivana Magovčević-Liebisch resigned as Director at Spyre Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

Ivana Magovčević-Liebisch, Ph.D., J.D. and Hunter C. Smith, M.B.A. resigned from the Board.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Spyre Therapeutics, Inc.: Amended and restated Certificate of Incorporation to change company name from Aeglea BioTherapeutics, Inc. to Spyre Therapeutics, Inc (effective 2023-11-28).

Change: charter amendment
Effective: 2023-11-28

Exact text from the filing

On November 27, 2023, the Company filed an amended and restated Certificate of Incorporation ("Amended and Restated Certificate of Incorporation") with the Secretary of State of the State of Delaware to change the name of the Company from "Aeglea BioTherapeutics, Inc." to "Spyre Therapeutics, Inc." (the "Name Change")

View on SEC.gov

48 governance changes filed in the last 30 days. Browse all governance changes →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-283693

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.